OPINION
NEWS
REGIONS
WORLD
BUSINESS
SPORTS
ENTERTAINMENT
LIFESTYLE
THE SUNDAY TIMES
SPECIAL FEATURES
SPECIAL SECTIONS
TMT NEWSWIRE
FAST TIMES
LEGAL ADVICE
CAMPUS PRESS
VIDEOS
EXPATS & DIPLOMATS
PHOTOS
BUSINESS FORUM
PODCASTS
RESOURCES
WEATHER
MARKET OVERVIEW
EXAM RESULTS
TMT CSI
TMT DIGITAL EDITION
GAMES
TMT 125TH ANNIVERSARY
QUIZZES
TMT Newswire > GlobeNewswire
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
by GlobeNewswire
Oct 08, 2024 7:43 pm

- Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases -

- Cardiovascular Scientific Advisory Board expected to provide strategic guidance as Tourmaline advances pacibekitug towards potential Phase 3 clinical trial readiness in 2025 for the treatment of cardiovascular diseases -

Register to unlock this article

Register to read this story and more for free.

Signing up for an account helps us improve your browsing experience.

Continue

OR

See our subscription options.

Already have an account? Log in here

Related Articles

PLEMCo Completes Design Build System

Nebraska Medicine expands cancer care with notable name

Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical Innovation

Key-Whitman Eye Center Selects Nextech

Cayuga Centers Hosts Live Foster Parent Q&A Event

Derivio Launches "Play-to-Earn” Telegram DApp, Integrating Social Engagement and Gameplay

American Indian College Fund Celebrates National Transfer Student Week